ORIGINAL RESEARCH article

Front. Public Health

Sec. Aging and Public Health

Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1553747

This article is part of the Research TopicThe Impact of Advancing Global Oncology: Towards Equity in Precision Prevention and MedicineView all 6 articles

The global, regional, and national prostate cancer burden and trends from 1990 to 2021, results from the Global Burden of Disease Study 2021

Provisionally accepted
Xiaomu  LiuXiaomu LiuHaiou  JiangHaiou Jiang*
  • The First Affiliated Hospital of China Medical University, Shenyang, China

The final, formatted version of the article will be published soon.

The rising annual incidence of prostate cancer (PCa) has become a significant health challenge for men worldwide. The study aims to estimate the contemporary disease burden of PCa across global, regional, and national levels.Methods: Data from the Global Burden of Disease Study 2021 (GBD 2021) were analyzed to evaluate trends in PCa incidence, prevalence, disability-adjusted life years (DALYs), and mortality from 1990 to 2021. Determinants of PCa burden were investigated through Spearman correlation analysis with socio-demographic index (SDI), decomposition analysis, and frontier analysis to assess regional improvement potential.: In 2021, global PCa incidence reached 1.32 million cases [95% uncertainty interval (UI): 1217320.93, 1400222.17]. Between 1990 and 2021, the global estimated annual percentage change (EAPC)s of age-standardized incidence rates (ASIR),prevalence rates (ASPR), DALYs rates (ASDR), and mortality rates (ASMR) were declined or increased at -0.06% [95% confidential interval (CI): -0.21, 0.08], 0.42% (95% CI: 0.26, 0.58), -0.96% (95% CI: -1.05, -0.87), and -0.58% (95% CI: -0.73, -0.44), respectively. Low-middle SDI countries exhibited the steepest rate increases, with males over 50 years being most affected. Significant positive correlations emerged between SDI levels and ASIR (R = 0.543, P < 0.001) or ASPR (R = 0.709, P < 0.001), whereas EAPC of ASDR (R = -0.430, P < 0.001) or ASMR (R = -0.450, P < 0.001) inversely correlated with SDI among 204 countries and territories. Decomposition analysis revealed the global increase of DYLYs for PCa was predominantly attributed to aging (77.65%) and population growth (58.59%). Frontier analysis identified substantial improvement potential across development spectra, particularly in middle to high SDI regions.Our findings demonstrated that despite slight modest declines in ASDR and ASMR within high SDI regions, PCa burden metrics persistently increased in lowmiddle SDI quintile. Nations across all development levels require urgent implementation of evidence-based policies and precision management strategies to mitigate this growing public health challenge.

Keywords: Global Burden of Disease study, prostate cancer, Prevalence, Incidence, Disability-adjusted life years, Mortality

Received: 31 Dec 2024; Accepted: 21 Apr 2025.

Copyright: © 2025 Liu and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Haiou Jiang, The First Affiliated Hospital of China Medical University, Shenyang, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more